Hansoh Pharmaceutical Group Company Limited reported no changes to its share structure for the month ended 30 June 2026. Issued ordinary shares remained at 6.06 billion, with zero treasury shares outstanding.
Authorised capital stayed unchanged at 20 billion ordinary shares with a par value of HKD 0.00001, equivalent to authorised share capital of HKD 0.20 million.
The company confirmed compliance with the Hong Kong Stock Exchange’s public-float requirement, maintaining at least the initial prescribed threshold of 16.21%.
Convertible securities on the balance sheet comprise zero-coupon convertible bonds due 2033, totalling HKD 4.68 billion. If fully converted at the set price of HKD 57.39 per share, these instruments could add up to 81.55 million new shares—about 1.35% of current outstanding shares. No conversions were executed during June.
Hansoh Pharma disclosed no outstanding share options, warrants, or other share-issuance arrangements during the period. The monthly return was submitted by Joint Company Secretary Ms. Guo Ying on 3 July 2026.
